Immutep unveils dual breakthroughs at ESMO 2025, strengthening case for Efti across multiple tumour types

Immutep (ASX:IMM) has unveiled a pair of significant clinical developments that underscore its ambition to reshape cancer treatment, announcing positive results in both soft tissue sarcoma and first-line non-small cell lung cancer at the 2025 European Society for Medical Oncology Congress in Berlin. …